Achieving HbA1c targets in clinical trials and in the real world: A systematic review and meta-analysis

Journal of Endocrinological Investigation

Volumn 37, Issue 5, 2014, Pages 477-495

  Mannucci, Edoardo ^a   Monami, Matteo ^b   Dicembrini, Ilaria ^a   Piselli, Attilio ^c   Porta, Massimo ^c  

^a Careggi Teaching Hospital   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Diabetes; HbA1c targets; Systematic review and meta analysis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AGE; BODY MASS; CAUCASIAN; CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; EMBASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTERVENTION STUDY; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PHARMACEUTICAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; BLOOD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HYPERGLYCEMIA; PERSONALIZED MEDICINE; PRACTICE GUIDELINE;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; OBSERVATIONAL STUDY AS TOPIC; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84900549912     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0069-6     Document Type: Review

References (49)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229-234 (Pubitemid 28350165)
2. Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287(19):2570-2581 (Pubitemid 34517204)
3. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
4. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
5. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560-2572
6. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N (2009) Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 19(9):604-612
7. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169
8. Inzucchi SE, Bergenstal RM, Buse JB, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364-1379
9. American Association of Clinical Endocrinologist (2007) Medical guidelines for clinical practice for the management of diabetes mellitus. http://www.aace.com
10. IDF Clinical Guidelines Task Force (2006) Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 23(6):579-593
11. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264-269
12. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trial 17(1):1-12 (Pubitemid 26120810)
13. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
14. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634 (Pubitemid 27387172)
15. Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjörnsdóttir S, Eliasson B, Steering Committee of the Swedish National Diabetes Register (2007) Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 30(3):496-502 (Pubitemid 46354324)
16. Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdóttir S (2005) The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med 22:1420-1426 (Pubitemid 41391321)
17. Bruno G, Merletti F, Bargero G et al (2008) Changes over time in the prevalence and quality of care of type 2 diabetes in Italy: the Casale Monferrato surveys, 1988 and 2000. Nutr Metab Cardiovasc Dis 18:39-45 (Pubitemid 350297894)
18. Saydah SH, Fradkin J, Cowie CC (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342 (Pubitemid 38101606)
19. Ford ES, Li C, Little RR, Mokdad AH (2008) Trends in A1C concentrations among US adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 31:102-104
20. Hovind P, Tarnow L, Rossing K et al (2003) Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 26:1258-1264 (Pubitemid 36929282)
21. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK (2008) The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. The twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115:1859-1868
22. Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. NEJM 366:1227-1239
23. Sharma SK, Joshi SR, Kumar A, Unnikrishnan AG, Hoskote SS, Moharana AK, Chakkarwar PN, Vaz JA, PRESENT Study Group (2008) Efficacy, safety and acceptability of biphasic insulin as-part 30 in Indian patients with type 2 diabetes: results from the PRESENT study. J Assoc Physicians India 56:859-863
24. Sharma SK, Al-Mustafa M, Oh SJ, Azar ST, Shestakova M, Guler S, Vaz JA (2008) Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. Curr Med Res Opin 24(3):645-652 (Pubitemid 351428975)
25. Hanberger L, Samuelsson U, Lindblad B, Ludvigsson J, Swedish Childhood Diabetes Registry SWEDIABKIDS (2008) A1C in children and adolescents with diabetes in relation to certain clinical parameters: the Swedish Childhood Diabetes Registry SWEDIABKIDS. Diabetes Care 31(5):927-929 (Epub 2008 Jan 30)
26. Pan CY, Ho LT, Soegondo S, Prodjosudjadi W, Suwanwalaikorn S, Lim SC, Chan TM, Chow KW, Thoenes M, Choi DS, DEMAND Study Investigators (2008) Prevalence of albuminuria and cardiovascular risk profile in a referred cohort of patients with type 2 diabetes: an Asian perspective. Diabetes Technol Ther 10(5):397-403
27. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Wang Y, Foley JE (2008) Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 25(4):435-441 Epub 2008 Mar 13
28. Cheung NW, Conn JJ, d'Emden MC, Gunton JE, Jenkins AJ, Ross GP, Sinha AK, Andrikopoulos S, Colagiuri S, Twigg SM, Australian Diabetes Society (2009) Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust 191(6):339-344
29. Plöckinger U, Topuz M, Langer M, Reuter T (2010) Problems of diabetes management in the immigrant population in Germany. Diabetes Res Clin Pract 87(1):77-86
30. Kaplan SH, Billimek J, Sorkin DH, Ngo-Metzger Q, Greenfield S (2010) Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects. Med Care 48(6 Suppl):16
31. (Diabetes Res Clin Pract. 2006; 73(2):198-204)
32. Tong PC, Ko GT, So WY, Chiang SC, Yang X, Kong AP, Ozaki R, Ma RC, Cockram CS, Chow CC, Chan JC (2008) Use of antidiabetic drugs and glycaemic control in type 2 diabetes - The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 82(3):346-352
33. Elis A, Rosenmann L, Chodick G, Heymann AD, Kokia E, Shalev V (2008) The association between glycemic, lipids and blood pressure control among Israeli diabetic patients. QJM 101(4):275-280 (Pubitemid 351426133)
34. Erasmus RT, Blanco Blanco E, Okesina AB, Gqweta Z, Matsha T (1999) Assessment of glycaemic control in stable type 2 black South African diabetics attending a peri-urban clinic. Postgrad Med J 75(888):603-606 (Pubitemid 29452589)
35. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E (2005) Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 28(3):514-520 (Pubitemid 40315306)
36. Saydah SH, Fradkin J, Cowie CC (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291(3):335-342 (Pubitemid 38101606)
37. McAlister FA, Majumdar SR, Eurich DT, Johnson JA (2007) The effect of specialist care within the first year on subsequent outcomes in 24,232 adults with new-onset diabetes mellitus: population-based cohort study. Qual Saf Health Care 16(1):6-11 (Pubitemid 46347943)
38. Muggeo M, Verlato G, Bonora E et al (1995) The Verona Diabetes Study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia 38:318
39. Trento M, Gamba S, Gentile L, ROMEO Investigators et al (2010) Rethink Organization to iMprove Education and Outcomes (ROMEO): a multicenter randomized trial of lifestyle intervention by group care to manage type 2 diabetes. Diabetes Care 33(4):745-747
40. Gill G (2003) Intensified treatment of type 2 diabetes - positive effects on blood pressure, but not glycaemic control. QJM 96:833-836
41. Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. NEJM 358:2545-2559 (Pubitemid 351831356)
42. Gaede P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. NEJM 348:383-393 (Pubitemid 36159355)
43. Haugstvedt A, Wentzel-Larsen T, Graue M, Søvik O, Rokne B (2010) Fear of hypoglycaemia in mothers and fathers of children with Type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med 27(1):72-78
44. Drew LM, Berg C, King P et al (2011) Depleted parental psychological resources as mediators of the association of income with adherence and metabolic control. J Fam Psychol 25(5):751-758
45. Reach G, Michault A, Bihan H et al (2011) Patients' impatience is an independent determinant of poor diabetes control. Diabetes Metab 37:497-504
46. Reach G (2011) Obedience and motivation as mechanisms for adherence to medication: a study in obese type 2 diabetic patients. Patient Prefer Adherence 5:523-531
47. Hirsch IB, Brownlee M (2010) Beyond haemoglobin A1c - need for additional markers of risk for diabetic microvascular complications. JAMA 303:2291-2292
48. Hemmingsen B, Lund SS, Gluud C et al (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343:d6898
49. Standards of Medical Care in Diabetes (2012) Diabetes Care 35:S11-S63